Transcatheter aortic valve implantation. European reimbursement report

Tuesday, May 30, 2017 Heart Disease News
Email Print This Page Comment
Font : A-A+

LONDON, May 30, 2017 /PRNewswire/ -- Transcatheter aortic valve implantation (TAVI) is used for the replacement of aortic

valves through vessels or minimally-invasive transapical routes in patients suffering from aortic stenosis and for whom open heart surgery is contraindicated or could lead to high mortality risk. Download the full report: https://www.reportbuyer.com/product/4890876/TAVI
is a well-established treatment option in Europe. The report explores reimbursement situations for TAVI using both transluminal and transapical access in 11 European countries: Austria, Belgium, Denmark, England, France, Germany, Italy, the Netherlands, Norway, Sweden and Switzerland. The report also includes information about reimbursement systems for medical devices, procedure coding for TAVI, diagnosis coding, payment mechanisms, reimbursement tariffs, policy considerations by payers and policy-makers as well as restrictions on indications or scenarios for use of TAVI. Reimbursement tariffs are provided for the procedure with and without peri-operative complications, including stroke.Information for this research was obtained from publicly available sources provided by national authorities who maintain procedural classifications, develop national payment systems, and determine coverage policies in health care (including health technology assessment bodies). No payer interviews were performed with the exception of requests to authorities when clarifications about procedure coding or reimbursement status were required. TAVI is well established technology with reimbursement available in all studied European geographies. The main payment models are diagnosis-related group (DRG) for entire hospitalization, add-on reimbursement (England, France, Italy in some regions) and fee for procedure and material (Belgium). All geographies, but Italy, have specific procedure codes for TAVI. Brand-specific reimbursement is only available in Belgium and France, while in other countries reimbursement is established for the class of devices.Reimbursement differs for different types of access for procedure only in France, Germany and Switzerland. In Germany and Switzerland procedure with transapical access has higher reimbursement.Complications or stroke specifically do not impact allocation to DRG and reimbursement level in any of studied countries, with exception of France.Download the full report: https://www.reportbuyer.com/product/4890876/About ReportbuyerReportbuyer is a leading industry intelligence solution that provides all market research reports from top publishershttp://www.reportbuyer.comFor more information: Sarah Smith Research Advisor at Reportbuyer.com Email: query@reportbuyer.com Tel: +44 208 816 85 48 Website: www.reportbuyer.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/transcatheter-aortic-valve-implantation-european-reimbursement-report-300465553.html

SOURCE ReportBuyer



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook